Searched for
GSK ACQUISITION RAPT THERAPEUTICS
Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...- $10. 6 billion deal: GSK to buy US cancer specialist NuvalentBritish pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in c...
- Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapseThe US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
- Global Markets: European shares edge higher with banks in the lead; the Middle East in focusEuropean markets saw a rise on Tuesday. Banking stocks led the gains, with Italian lenders drawing attention. Tech stocks stabilized after ...
- GSK in talks to buy cancer biotech Nuvalent for more than $9 billionBritish drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Disc...
- One of UK's oldest listed cos Tate & Lyle accepts $3.6 billion bid from IngredionIngredion is set to acquire Tate & Lyle for 2.7 billion pounds, approximately 3.6 billion dollars. This deal marks the end of Tate & Lyle's...
- AOL, Vimeo parent Bending Spoons files for US IPOBending Spoons, an Italian tech firm, has filed for a US initial public offering. The company, which acquired AOL and Eventbrite, could be ...
- Carlyle-backed Viyash Scientific buys Italy’s BioForLife for Rs 188 croreViyash Scientific, backed by Carlyle, is acquiring Italy's BioForLife for Rs. 188 crore. This move aims to build a leading global companion...
- Haleon to invest Rs 2,000 crore to set up first India plantHaleon is investing Rs 2,000 crore to build its first manufacturing plant in Pithampur, India. This move sharpens its focus on India, a fas...
- Kiran Mazumdar-Shaw's Immuneel Therapeutics raises Rs 100 crore from Singularity AMC, Rainmatter, othersThe Bengaluru-based company makes CAR-T therapy, a form of cancer treatment where a patient’s own immune cells are taken out, trained in a ...
- Evonith Steel acquires Indrajit Power in Maharashtra for Rs 232 crEvonith Steel has successfully acquired Indrajit Power Pvt Ltd for Rs 232 crore. This acquisition was completed through an insolvency proce...
- Sorry Gen Z, but knowing therapy words doesn't make you emotionally intelligentAs therapy-related language becomes increasingly common, many people are questioning whether knowing mental health terminology automaticall...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concernsThe oral drug, pociredir, was being tested to treat sickle-cell disease, an inherited blood disorder that can trigger pain, anemia and or...
- Delhi HC allows Intas to sell cancer drug Bevatas, sets aside order favouring Sun PharmaThe Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medicati...
- Supriya Lifescience shares surge 17% on strong Q4 earnings; PAT rises 47% YoYSupriya Lifescience shares jumped over 16% after the company posted a strong Q4FY26 performance, with PAT rising 47% YoY and revenue surgin...
- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...
- GSK's chronic hepatitis B drug helps one in five achieve functional cure in key studiesGSK's experimental hepatitis B drug, bepirovirsen, showed promising results in late-stage studies, with nearly one in five patients achievi...
Load More
